Summary: ABCC2/Abcc2 is a member of the ABC transporter family expressed mainly in the liver bile canalicular membrane and involved in the excretion of various kinds of organic anions from hepatocytes into bile. During the drug development process, species differences in the pharmaco-and toxicokinetics of candidate drugs are a major problem. It is possible that ABCC2/Abcc2 transport activity as well as inhibitor sensitivity could lead to a number of phenomena (e.g. a difference in the biliary excretion clearance, a delay in the elimination half-life from the circulating blood and toxic side effects on ABCC2 -mediated drug-drug interactions, such as drug-induced hyperbilirubinemia). From this point of view, it is useful to be able to predict during preclinical development if certain compounds of interest are substrates and/or modulators of ABCC2. Although an in vivo animal model or an in vitro model expressing ABCC2 are useful assay systems, these have some limitations as far as predicting the transport profile of compounds in vivo is concerned. I will present an overview of the species differences in the tissue distribution, function, and also characteristic transport properties of ABCC2/Abcc2 mainly in an in vitro experimental model.
Introduction
ABCC2 is an organic anion transporter expressed on the apical membrane of polarized cells, such as hepatocytes, renal epithelia, intestinal epithelia, and placenta. 1, 2) It is involved in the phase III excretion of a wide range of organic anions, including glutathione conjugates, glucuronide conjugates, sulfated conjugates of bile salts as well as non-conjugated compounds from hepatocytes into bile, or from renal epithelia into urine, or from intestinal epithelia into the intestinal lumen. [1] [2] [3] The endogenous ABCC2/Abcc2 substrates include glutathione (GSH) which is the major osmolyte in bile. The concentration of GSH in bile is as high as 10-15 mM, while that in the blood is as low as 100 mM, and so the steep concentration gradient from bile to blood drags water into bile and finally generates part of the bile flow (bile salt-independent bile flow). Supporting the importance of Abcc2 in the formation of bile flow, animals lacking Abcc2 exhibit approximately half the bile flow rate of control animals. 4, 5) Bilirubin and its glucuronide conjugates are also substrates of ABCC2/Abcc2. Genetic defects in ABCC2 expression/function result in DubinJohnson syndrome with mild jaundice in humans because of the retarded excretion of bilirubin and its glucuronide forms into bile. 6, 7) Such pathogenic effects have also been confirmed in animals with a hereditary defect in Abcc2. Eisai hyperbilirubinemic rats (EHBR), and TR -/GY, found in Japan and the Netherlands, respectively, have long been used as animal models of Dubin-Johnson syndrome. [8] [9] [10] A single nucleotide mutation or deletion in the cDNA region encoding Abcc2 results in a loss of functional Abcc2 in these model rats. [11] [12] [13] In addition, hyperbilirubinemia has recently been confirmed in Abcc2 knock-out mice. 14) Species differences in ABCC2/Abcc2 expression It is widely accepted that ABCC2/Abcc2 is primarily expressed in the liver of various species. However, the expression level of ABCC2/Abcc2 in the liver is not always higher than that in other tissues. Conrad et al. 15) reported that the tissue distribution pattern of ABCC2/Abcc2 was similar in humans and rats, namely, it was found in the liver, kidney and small intestine. However, in contrast to rats, [11] [12] [13] mice 16) and humans, 17) the expression level in the dog liver was lower than in the dog kidney. 15) This lower ABCC2/Abcc2 expression in the liver has also been reported in rabbits (small intestineÀkidney:liver). 18) Moreover, in monkeys, Abcc2 mRNA and protein are only weakly detectable in the liver. 19) We also have tried to quantify the absolute Abcc2 protein expression in animal livers by using appropriate rabbit anti-ABCC2/Abcc2 antisera combinations and respective recombinant antigens. 20, 21) As a result, it was found that the relative protein expression of Abcc2 in the liver of beagle dogs was about 10% of that in SD rat liver. These findings correspond well to the reported rank order of in vivo biliary excretion clearance of temocaprilat and the in vitro transport activity of dinitrophenyl glutathione (DNP-SG), both Abcc2 substrates, into canalicular membrane vesicles (CMVs) in rats, mice, rabbits and dogs. 22) The large difference in the biliary excretion clearance of certain organic anions could be at least partly explained by differences in the expression level of Abcc2 in the liver.
Although the expression of Abcc2 in brain has long been controversial, its presence is now firmly established. It is inducible as demonstrated in rats and humans. Abcc2 is not detected in normal rat brain but induced in the brain in animal models of epilepsy, and has been implicated in resistance to anti-epileptic drugs. [23] [24] [25] Potschka et al. demonstrated that the brain-to-plasma concentration ratio of phenytoin was significantly higher in Abcc2-deficient rats (TR -) compared with normal Wistar rats. Moreover, coadministration of probenecid, a known Abcc2 inhibitor, increased the pharmacological activity of phenytoin without affecting its systemic exposure, most likely because of its enhanced brain penetration. In TR -rats, significantly increased interstitial brain concentrations of phenytoin have been observed. 24) Although circumstantial evidence suggests that phenytoin is a transport substrate of rat Abcc2, direct evidence is required using in vitro rat Abcc2 expression system. In humans, ABCC2 expression has been observed in the hippocampal region especially in blood vessels from many patients with hippocampal sclerosis. 26) Baltes et al. carried out further studies to see if phenytoin is a transport substrate for known ABC transporters expressed in the brain and found that phenytoin was only transported by mouse Abcb1a/Mdr1a but not by mouse Abcb1b/Mdr1b, human ABCB1/MDR1 and human ABCC2. 27) Although ABCC2 is one of the most significantly upregulated ABC transporters in endothelial cells (＋225%) isolated from temporal lobe blood vessels of patients with refractory epilepsy compared to control vessels from aneurysm domes and umbilical vein, 28) contribution of human ABCC2 to the efflux of phenytoin from brain to systemic blood is limited, if any. Considering the differences in the transport of ABCC2/Abcc2 among species, it is still possible that rat Abcc2 accepts phenytoin as a transport substrate. Abcc2 expression in brain is sometimes strainspecific. 29) In C57BL/6 mice, a large subset of brain blood vessels was distinctly labeled with rabbit anti-Abcc2 antibody, whereas in FVB mice no staining was detected in brain. However, in both strains, the biliary canaliculi in the liver and tubule in the kidney were strongly immunoreactive. 29) The above observations imply that the tissue distribution pattern of ABCC2/Abcc2 differs from one species to another (and also from strain to strain) and is sometimes inducible under certain conditions.
Species differences in ABCC2/Abcc2 transport function
It is useful to assess the possibility that a compound of interest is a substrate/inhibitor of ABCC2 because such information is important for predicting the biliary excretion capacity or drug-drug interaction potential involving ABCC2 during the preclinical stage of development. There are several in vitro assay systems evaluating the transport function of ABC family as summarized in Figure 1 and Table 1 . Among these, most frequently used system for ABCC2/Abcc2 is vesicle transport assay system using membrane vesicles from animal liver (CMVs) or recombinant gene expressing cells. Utilizing such experimental systems, a huge amount of informa- Fig. 1 . In vitro assay systems evaluating the transport function of ABC family (A) Vesicle transport assay; membrane vesicles from animal liver (CMV) or from in vitro gene transfected cells were prepared. These vesicles are mixture of inside-out and right side-out vesicles. As ATP is relatively impermeable to the membrane and nucleotide binding domain (NBD, shown as black portion of the oval), which catalyzes ATP hydrolysis to produce transport energy, is located on the intracellular side, transport reaction only by inside-out vesicle is observed. Transport in the presence of AMP is subtracted from that in the presence of ATP to calculate ATP-dependent transport. (B) ATPase assay; Membrane fraction (vesiculization is not necessary) is incubated with ATP in the presence or absence of test compound. ATPase activity is evaluated by monitoring the production of inorganic phosphate as a result of ATP hydrolysis. This assay system is based on the consideration that ATP hydrolysis is stimulated by the presence of substrate as an transport energy. (C) Efflux assay; Cells expressing ABC transporter of interest are preloaded with test compound in the absence of glucose but with metabolic inhibitors at low temperature to deplete cellular ATP. Under such condition, ABC transporter function is suppressed thus the compound is successfully accumulated. Then, medium is changed to normal warm medium containing glucose without metabolic inhibitor to replete cellular ATP. Finally, efflux activity is evaluated by monitoring the extracellular or intracellular concentration of test compound. (D) Transcellular transport assay; Polazized epithelial cells, such as MDCK, LLC-PK1, Caco2 cells, are cultured on transwell filter. Test compound is added to either of the apical or basal side of the transwell chamber. Transport activity is evaluated by measuring the concentration change of the test compound in the opposite chamber. For compounds with low membrane permeability, it is sometimes necessary to express uptake carrier supporting efficient transcellular transport. 63, 64) tion about the substrate specificity of human and rat ABCC2/Abcc2 is now available.
2)
Overall, the substrate specificity of ABCC2/Abcc2 among different species is similar, however the transport efficiency and modulator sensitivity are not as indicated below.
We compared the intrinsic transport activity of Abcc2 from rats, mice, dogs, and monkeys expressed in Sf9 cells after normalizing the Abcc2 expression level. 20, 21) For the four compounds tested (estradiol-17-b-D-glucuronide (E217bG), leukotriene C4 (LTC4), bromosulfophthalein (BSP), and CCK-8), we found that the Abcc2 from these animals generally had a similar substrate specificity. However, strictly speaking, the transport activities differed from one species to another. Importantly, the rank order of the transport activity (pmol/min/nmol Abcc2 molecule) depends on the substrates. For example, the transport activity for LTC4 is highest for monkeys followed by other species with approximately half the activity of monkey Abcc2 (Fig. 2) . While the transport activity for E217bG is highest in rats and dogs, it is considerably lower in monkeys and mice (Fig. 2) . Species differences in the disposition of some ABCC2/Abcc2 substrates have also been reported in vivo. Tian et al. reported that the biliary excretion mechanism of fexofenadine is different in rats and mice. 30) The biliary excretion of fexofenadine was not affected in TR -rats compared with normal Wistar rats, while it was reduced by 85% in Abcc2 knockout mice compared with normal mice. The ATP-dependent transport of LTC 4 and E 2 17bG into membrane vesicles from Sf9 cells expressing Abcc2s. The membrane vesicles from rat Abcc2 (), mouse Abcc2 (), dog Abcc2 (), monkey Abcc2 ($) and green fluorescent protein (GFP, as a negative control) () expressing Sf9 cells were incubated in medium containing Thus, the biliary excretion of fexofenadine is primarily dependent on Abcc2 in mice but not in rats. The difference between the pharmacokinetics of mycophenolic acid (MPA) in rats and humans is caused by the different affinities of ABCC2/Abcc2 for the glucuronide form. 31) It will be possible to calculate the transport clearance of Abcc2 substrates across the canalicular membrane by multiplying the transport clearance of the Abcc2 molecule (ml/min/pmol Abcc2 molecule) and absolute Abcc2 protein expression in the liver (pmol Abcc2 molecule/g liver).
Functional difference of ABCC2/Abcc2 among species is likely attributable to the primary sequence of the amino acids. ABCC2/Abcc2 sequences are reported in 14 animal species. As shown in Table 2 , human ABCC2 has the highest homology with primates including Chimpanzee and Rhesus monkey, followed by other mammalians.
The mode of recognition/transport of substrate by ABCC2/Abcc2 is characterized by using mutant transporter proteins with artificial amino acid substitution especially within or in the vicinity of transmembrane (TM) domains of human ABCC2 and rat Abcc2. Several studies including our own have found that charged amino acids in the TM domains are involved in the substrate recognition/transport [32] [33] [34] ( Fig. 3) . In some cases, substitution of these specific amino acids into neutral amino acids decreased the transport of glutathione conjugate but increased that of glucuronide conjugates, 33) and in some cases, substitution of arginine at 586 (located in TM6) or 1096 (located in TM11) of rat Abcc2 resulted in acquiring transport activity for taurocholate, which is not a substrate for wild type rat Abcc2. 32) These results indicated that charged amino acids are involved in the formation of substrate recognition/transport pocket of Abcc2. In addi- Putative TM domains were indicated by underlines. Amino acid positions known to be important for substrate recognition/transport of the substrates are indicated by arrows with``h'' or``r''. In those studies, transport activity was affected by substituting those amino acids with others in human ABCC2 (h) or rat Abcc2 (r). [32] [33] [34] [35] [36] tion, amino acids in cytoplasmic region are also important for the recognition/transport of substrates. In human, substitution of proline at 1158 located in the cytoplasmic loop between TM15 and TM16 to alanine results in decreased transport of LTC4 but E217bG and MTX transport was unaffected. 35) Similarly, tryptophan at 1254 located in the vicinity of TM17 of human ABCC2 cytoplasmic region is also important for recognition/transport of its substrates. 36) However, these amino acids are almost well preserved among different animal species known to date (Fig. 3) , thus species difference in the substrate specificity is not solely accounted for by these amino acids but other unidentified amino acids or those combination will account for the functional difference of ABCC2/Abcc2 between species.
Accumulating evidence suggests that ABCC2/Abcc2 does not have a simple mechanism of interaction with compounds. Moreover, there are species differences in the transport characteristics, especially with regard to the transport modulation by other copresent compounds. Zimmermann et al. found overlapping substrate specificity between human and rat ABCC2/Abcc2, however, the transport efficiency and modulation effect by other compounds is markedly different between these two species. 37) Typical example includes that sulfinpyrazone inhibits E217bG transport by mouse Abcc2, while it stimulates that by human ABCC2. We also found that the transport of E217bG was stimulated in mouse and monkey Abcc2, while it was inhibited in rat and dog Abcc2 by 4-methylumbelliferyl-b-D-glucuronide (MUG). 20, 21) Such complex alterations in transport produced by other compounds will be discussed below.
Modulation of ABCC2/Abcc2 transport activity by a variety of compounds
Substrate recognition by ABCC2/Abcc2 is complex. It is now considered that ABCC2/Abcc2 has multiple recognition sites for substrates and modulators. Note that the K m value is reduced nearly 10-fold while the change in V max is only 2-fold. 46) 399 ABCC2/Abcc2 in Different Environments presence of multiple substrate recognition sites was originally demonstrated for ABCC1. Loe et al. were the first to show that the ATP-dependent transport of vincristine into ABCC1-expressing membrane vesicle only occurred in the presence of GSH. 39) Subsequently, van Aubel demonstrated in rabbit Abcc2 that the ATP-dependent transport of vinblastine only occurred in the presence of GSH, and ATP-dependent transport of GSH was only observed in the presence of vinblastine. 40) Bakos et al. carried out a detailed examination of stimulatory effects of a variety of compounds on the uptake of N-ethylmaleimide glutathione (NEM-GS) into membrane vesicles isolated from Sf9 cells expressing human ABCC2. 41) Such stimulatory effects were not only observed in membrane vesicles but also confirmed in intact cell systems expressing human ABCC2. 42, 43) Evers et al. quantitatively demonstrated that indomethacin and sulfinpyrazone stimulated GSH efflux into the apical compartment of MDCKII cells expressing ABCC2 at lower concentrations (º50 mM for indomethacin and º800 mM for sulfinpyrazone), while it produced inhibition at higher concentrations (À100 mM for indomethacin and À1.6 mM for sulfinpyrazone). Zelcer 44) and Bodo 45) carried out a detailed study of the stimulatory effect of transport in membrane vesicles expressing human ABCC2 in Sf9 cells, and a model was finally proposed by Borst et al. 38) This model is based on the observation that ABCC2/Abcc2 transport activity is stimulated in the presence of other compounds (heterotropic cooperativity) or even by itself (homotropic cooperativity). 44, 45) The combination of substrates and modulators for human and rat ABCC2/Abcc2 is summarized in Table 3 . In some cases, these modulators exhibit a stimulatory effect at lower concentrations but an inhibitory effect at higher concentrations. The model proposed by Borst et al.
elegantly explains such phenomena by assuming multiple sites on ABCC2/Abcc2, namely, the substrate binding site (S-site) and the modulator binding site (M-site). 38) The modulator compound initially binds to the M-site at low concentrations to stimulate substrate transport (substrate binding to substrate site). As the concentration of the modulator increases, it also binds to the S-site and sometimes is transported. As a result, the transport of other substrates is competitively inhibited by the presence of a high concentration of modulator compound. For example, sulfinpyrazone has been identified as such a compound. ABCC2-mediated efflux of GSH into the apical medium of MDCKII cells expressing ABCC2 was stimulated in a concentration-dependent manner up to 0.8 mM, while it was inhibited at concentrations higher than 1.6 mM sulfinpyrazone. 42) Sulfinpyrazone is also transported by ABCC2 at concentrations higher than 1.6 mM. The authors suggested that sulfinpyrazone binds to the modulator site with high affinity to stimulate GSH excretion, while at higher concentrations, it binds to the substrate binding site to block GSH transport with low affinity. Kinetic analysis revealed that the stimulation of transport was attributable to a reduction in the Km value for substrate transport. Chu et al. demonstrated that the Km value for ethynylestradiol glucuronide (EE-G) uptake by ABCC2 was markedly reduced compared with that in the absence of ethylnylestradiol sulfate (EE-S), whereas the Vmax value was only slightly higher than that in the absence of EE-S (Fig. 4) . 46) This finding suggests that binding of EE-S results in a conformational change in ABCC2 and increases its affinity for other substrates.
We have demonstrated that Abcc2-mediated GSH excretion is enhanced by the bolus injection of benzylpenicillin (PCG) in SD rats but not in EHBR and concomitant choleresis was observed in SD rats. 47) The in- The modulator concentration with maximal effect is shown. The substrate concentration used is indicated in parenthesis with the maximum stimulatory effect (xfold increase). For example, the transport of E 2 17bG (1 mM) was maximally stimulated 3.8-fold in the presence of 1 mM probenecid as shown in the upper left hand column of the table. In some cases, examples of transport inhibition were included in the table with fold change ratio of less than 1.0, to emphasize the presence of multiple substrate/modulator recognition sites in ABCC2/Abcc2. Data were obtained from transport experiments using Sf9 cell membrane vesicles expressing ABCC2/Abcc2 if otherwise indicated. * 1 Endogenous GSH export was examined in cells transfected with ABCC2/Abcc2. * 2 Transcellular transport was examined in MDCKII cells transfected with ABCC2/Abcc2. Fold stimulation effect in transcellular transport experiments was calculated as follows; apical/basal transport ratio was calculated for ABCC2/Abcc2-transfected and parent MDCKII. ABCC2/Abcc2-mediated transport was then calculated by dividing the ABCC2/Abcc2-mediated transport in the presence of modulator by that in its absence. E 2 17bG; Estradiol-17-b-D-glucuronide, DNP-SG; dinitrophenyl glutathione, NEM-GS; Nethylmaleimide glutathione, MTX; methotrexate, EA-SG; ethacrynic acid glutathione, EE-G, ethynylestradiol-glucuronide. 401 ABCC2/Abcc2 in Different Environments crease in the bile flow correlated well with the GSH excretion rate into bile as shown in the correlation plot (Fig. 5A) . Such a stimulatory effect was also confirmed in vitro using ABCC2-expressing MDCKII cells (Fig. 5B) . ABCC2-mediated GSH efflux was enhanced by PCG in a concentration-dependent manner. In spite of the increase in bile flow, the GSH concentration in bile was increased approximately 1.5-fold compared with the control. 47) This observation strongly supports the hypothesis that GSH transport by Abcc2 is stimulated by the administration of PCG in vivo and results in choleresis (Fig.  5C) . Choleretics are classified into at least two categories; true choleretics and hydrocholeretics. A hydrocholeretic is a compound that itself or its metabolites undergoes concentrative excretion into bile to drag water without stimulating efflux transporters, such as Abcc2 and Abcb11. 48) On the other hand, a true choleretic is a compound that activates carrier-mediated transport of GSH and other organic anions as major osmolyte. Based on this criterion, PCG is a true choleretic because the biliary excretion rates of Abcc2 substrates, including bilirubin and GSH, were increased to a degree by PCG. On the other hand, probenecid is a typical example of a hydrocholeretic. Probenecid (1 and 5 mM) inhibits the GSH efflux in ABCC2-MDCKII as reported previously. 42) Concomitantly, the biliary excretion rate of GSH was inhibited almost completely by perfusion of 1 mM pronbenecid in isolated rat liver 49) while, under these conditions, the bile flow increased 2-fold. This was explained by the fact that active efflux of probenecid and its glucuronyl conjugates into bile canceled the inhibitory effect on Abcc2-mediated transport of GSH and other organic anions. 49, 50) This suggests that compounds which inhibit ABCC2/Abcc2 or ABCB11/Abcb11 function do not always act as cholestatics if they or their metabolites are actively excreted into bile.
Although such stimulatory effects of ABCC2/Abcc2 transport activity by the modulator compounds are well observed in vitro (Table 3) , its physiological/clinical significance is not established yet. Considering the in vivo unbound plasma concentrations of drugs in human, such stimulation is not likely to occur under clinical situation. Most of the stimulator concentration used in the vesicle transport study or transcellular transport study is 0.1-10 mM in the absence of albumin in the medium (Table 3) , while clinically achievable unbound plasma concentration of the compounds of interest are less than 1 mM. Even for benzbromarone, which is able to stimulate transcellular transport of docetaxel, paclitaxel, saquinavir and etoposide at as low as 2 mM (Table 3) , its plasma unbound concentration is calculated to be 50 nM (assuming the total concentration and plasma free fraction of ben-zbromarone are 5 mM and 0.01, respectively 51, 52) ), thus still difficult to induce stimulatory effect in vivo in clinical situation. Physiological/clinical significance of the stimulatory effect by those modulators on ABCC2/Abcc2-mediated transport needs to be further examined.
Factors affecting ABCC2/Abcc2 transport characteristics in heterogeneous expression systems
One of the most popular experimental systems for ABCC2/Abcc2 involves the Sf9-baculovirus expression system, where massive amounts of recombinant proteins are transiently expressed. Crude membrane vesicles isolated from the infected cells provide convenient assay material for in vitro transport assay. In actual fact, many reports have been published using this Sf9 membrane vesicle system expressing ABCC2/Abcc2. The overall transport properties of Abcc2 are similar between Sf9 cells and endogenous Abcc2 in CMVs from rat liver, although the rank order of the transport activity for various compounds differs between these two experimental systems. For example, the transport activity of Abcc2 for DNP-SG and E217bG was approximately 60 ml/min/mg protein and 200 ml/min/mg protein, respectively, in Sf9 cell membrane vesicles 33) and, so, the relative transport clearance is several fold higher for E217bG. On the other hand, the rank order of the transport clearance is reversed in CMVs from SD rat liver; 53) the transport activity of Abcc2 for DNP-SG and E217bG was approximately 35 ml/min/mg protein and 15 ml/min/mg protein, respectively, in CMV from SD rat liver and, so, the relative transport clearance is several fold higher for DNP-SG. Accordingly, the Km value for the transport of DNP-SG in Sf9 cell membrane vesicles was 81 mM while that in CMV was 20 mM, namely, 4-fold higher in Sf9 cells (lower affinity for DNP-SG in the Sf9 cell membrane). Since the Vmax values were about 10-fold larger for DNP-SG than E217bG in both CMV and Sf9 membrane vesicles, the difference in the Km value between these two systems may be the main cause of the discrepancy. Such a difference in the transport characteristics of heterogeneous experimental systems should be kept in mind especially when carrying out quantitative data analysis.
Recently, the cholesterol content has been considered as an important factor affecting the transport characteristics of other ABC proteins. It has been reported that the transport activity or properties of ABCG2/Breast cancer resistance protein (BCRP), another ABC transporter capable of transporting similar substrates to those of ABCC2, is quite different in Sf9 cells compared with that expressed in mammalian cells. There have been independent reports of such findings involving this issue. [54] [55] [56] Membrane cholesterol is 4-to 5-fold lower in the Sf9 cell membrane compared with the human cell membrane.
Cholesterol replenishment into Sf9 cells prior to vesicle isolation resulted in an increase in the ATP-dependent transport activity of estrone-3-sulfate. Cholesterol loading increased the Vmax more than 20-fold with relatively little change in the Km value (approximately 2-fold). 54) Similarly, methotrexate (MTX) transport into membrane vesicles isolated from Sf9 cells loaded with cholesterol was stimulated about 20-fold, and this was attributable to the increase in Vmax rather than a change in the Km value. 56) It is possible that ABCG2 requires membrane cholesterol for efficient substrate transport.
Another example demonstrating the importance of cholesterol in transporter drug recognition involves ABCB1 as reported by Kimura et al. They demonstrated that cholesterol directly binds to purified ABCB1 in a detergent soluble form and the effects of cholesterol on the Km values of drug-stimulated ATPase activity were inversely correlated with the molecular mass of the drugs tested. 57, 58) As most of the ABCB1 substrates are highly hydrophobic and structural analysis implies the presence of substrate recognition sites within the lipid bilayer, cholesterol may easily interact with the sites where drugs are recognized. 59) Alternatively, cholesterol interacts with putative modulator binding site of ABCB1, 60) though these two possibilities are hard to be distinguished.
Although there is no information about ABCC2/Abcc2 with regard to the sensitivity of transport in terms of membrane cholesterol content, it is possible that ABCC2/Abcc2 is also affected by cholesterol. Indeed, ABCC2/Abcc2 substrates have a hydrophobic nature to some extent and the TM domains of ABCC2/Abcc2 are also involved in substrate recognition/transport. [32] [33] [34] Moreover ABCC2/Abcc2 is embedded in the apical bile canalicular membrane in the liver, where the cholesterol content is higher compared with the opposite basolateral membrane. 61, 62) Conclusion Although ABCC2/Abcc2 shares similar overall substrate specificity in different animal species, the mode of substrate recognition is not so simple as described above. Not only the differences in the intrinsic transport activity of each substrate, but also the heterogeneous effect by the coexisting modulators in different animal species should be considered for better prediction of in vivo ABCC2/Abcc2 function. To this end, we need to find out the mechanism underlying the cause of such differences and fill in a quantitative and qualitative gaps in between heterogeneous experimental systems.
